Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Hansa Biopharma
  4. Hansa Biopharma — Februar 2026

Hansa Biopharma — Februar 2026

Planlagt Fastgjort Låst Flyttet Hansa Biopharma
44 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    LP90
    wrote on sidst redigeret af
    #7

    Godmorgen 🙂

    1 Reply Last reply
    0
    • exitnuE Offline
      exitnuE Offline
      exitnu
      wrote on sidst redigeret af
      #8

      God morgen 🙂

      1 Reply Last reply
      0
      • HenrikhotH Offline
        HenrikhotH Offline
        Henrikhot
        wrote on sidst redigeret af
        #9

        Godmorgen. Bliver spændende hvordan regnskabet ender, og ikke mindst forventninger til 2026.

        1 Reply Last reply
        0
        • HenrikhotH Offline
          HenrikhotH Offline
          Henrikhot
          wrote on sidst redigeret af
          #10

          Den største trigger er vel når Fda accepterer ansøgningen, og sætter pdufa-dato.

          1 Reply Last reply
          0
          • L Offline
            L Offline
            LP90
            wrote on sidst redigeret af
            #11

            Godmorgen 🙂

            1 Reply Last reply
            0
            • exitnuE Offline
              exitnuE Offline
              exitnu
              wrote on sidst redigeret af
              #12

              God morgen 🙂

              1 Reply Last reply
              0
              • exitnuE Offline
                exitnuE Offline
                exitnu
                wrote on sidst redigeret af
                #13

                Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results

                Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
                11 Feb 2026, 07:00
                Regulatory information

                · Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024.
                · Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation.
                · Successfully completed a directed share issue raising 671.5 MSEK (~ $71.3M).

                1 Reply Last reply
                0
                • exitnuE Offline
                  exitnuE Offline
                  exitnu
                  wrote on sidst redigeret af
                  #14

                  Link Preview Image
                  Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results | Hansa Biopharma

                  favicon

                  (www.hansabiopharma.com)

                  1 Reply Last reply
                  0
                  • exitnuE Offline
                    exitnuE Offline
                    exitnu
                    wrote on sidst redigeret af
                    #15

                    Financial Performance

                    Fourth‑quarter IDEFIRIX product sales reached 61.1 MSEK, a 139% increase from 25.6 MSEK in Q4 2024. Revenue totalled 76.0 MSEK, representing a 135% increase compared to 32.3 MSEK in Q4 2024.

                    1 Reply Last reply
                    0
                    • exitnuE Offline
                      exitnuE Offline
                      exitnu
                      wrote on sidst redigeret af
                      #16

                      Full‑year 2025 IDEFIRIX product sales amounted to 204.7 MSEK for the full year, a 46% increase from 140.1 MSEK in the previous year. Revenue totalled 222.3 MSEK, representing a 30% increase compared to 171.3 MSEK in 2024. This growth reflects continued adoption across major European markets and underscores both the clinical value of IDEFIRIX, and the momentum Hansa is building in the treatment of highly sensitized patients undergoing kidney transplantation

                      1 Reply Last reply
                      0
                      • exitnuE Offline
                        exitnuE Offline
                        exitnu
                        wrote on sidst redigeret af
                        #17

                        Interim Report
                        January - December 2025

                        https://www.hansabiopharma.com/files/Main/1219/4305662/hnsa--q4-2025-eng-final.pdf

                        1 Reply Last reply
                        0
                        • R Offline
                          R Offline
                          Rasbom
                          wrote on sidst redigeret af
                          #18

                          Mon ikke marked godkender dette regnskab. Jeg syntes det begynder at igen et gennembrud. Endelig........

                          1 Reply Last reply
                          0
                          • V Offline
                            V Offline
                            Vikinger
                            wrote on sidst redigeret af
                            #19

                            Hvis man kigger på deres hjemmeside, så er det under, selv de laveste forventninger til 2025, så det tror jeg da ikke vi skal tage specielt positivt.

                            1 Reply Last reply
                            0
                            • V Offline
                              V Offline
                              Vikinger
                              wrote on sidst redigeret af
                              #20

                              Link Preview Image
                              Analysts and consensus | Hansa Biopharma

                              We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.

                              favicon

                              (www.hansabiopharma.com)

                              1 Reply Last reply
                              0
                              • R Offline
                                R Offline
                                Rasbom
                                wrote on sidst redigeret af
                                #21

                                Jeg tænker i mindre grad på helårsresultatet, men mere på at de tilsyneladene har fået vendt de to sidste svage slagskvartaler til ny slagsfremgang.

                                1 Reply Last reply
                                0
                                • R Offline
                                  R Offline
                                  Rasbom
                                  wrote on sidst redigeret af
                                  #22

                                  Den starte oppe med 11% så er vi da igang. Så må vi se hvad det bliver til når marked lukker igen

                                  1 Reply Last reply
                                  0
                                  • exitnuE Offline
                                    exitnuE Offline
                                    exitnu
                                    wrote on sidst redigeret af
                                    #23

                                    Conference Call Details

                                    Hansa Biopharma will host a telephone conference today Wednesday, 11 February 2026, at 14:00 CET / 8:00 am EST.

                                    Join the webcast here:

                                    Link Preview Image
                                    Registration | Hansa Biopharma Fourth Quarter 2025 Earnings

                                    Hansa Biopharma Fourth Quarter 2025 Earnings

                                    favicon

                                    (event.choruscall.com)

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      LP90
                                      wrote on sidst redigeret af
                                      #24

                                      same same story hver eneste gang den sidste lange periode når den kommer over 40 så trykkes den ned igen ???? fatter ikke folk sælger det er jo en vinder på den bare lidt længere bane

                                      1 Reply Last reply
                                      0
                                      • R Offline
                                        R Offline
                                        Rasbom
                                        wrote on sidst redigeret af
                                        #25

                                        Ja det er frustrende at se Hansa blive trykket ned endnu en gang. Er det gevinsthjemtagning med frygt for at Hansa ikke for priority review tilkendt. Hvilket som jeg har forstået det skulle ske snart. Hvis de får det.

                                        1 Reply Last reply
                                        0
                                        • CupcakeC Offline
                                          CupcakeC Offline
                                          Cupcake
                                          wrote on sidst redigeret af
                                          #26

                                          Relativ volumen var 83% i dag, og VWAP ligger på 37,48 mod seneste handel i 35,90. Det ligner lidt, at træet er blevet rystet for at tage nogle stop-loss. Som LP90 også har skrevet før, er der et ret tydeligt mønster omkring 40-niveauet, så man kan jo svinge lidt med en del af positionen, hvis man har lyst. Med en FDA-godkendelse i sigte burde casen egentlig løfte sig, men FDA virker noget uforudsigelig for tiden.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper